Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/11/2024
• Auteurs : Julian TheurietMarion MasingueAnthony BéhinAna FerreiroGuillaume BassezPauline JaubertOriana TarabayFrédéric FerAntoine PegatFrançoise BouhourJuliette SvahnPhilippe PetiotLaurentiu JomirGuy ChauplannazCatherine Cornut-ChauvincVéronique ManelEmmanuelle Salort-CampanaShahram AttarianEtienne FortanierAnnie VerschuerenLudivine KoutonJean-Philippe CamdessanchéCéline TardArmelle MagotYann PéréonJean-Baptiste NouryMarie-Christine Minot-MyhieMaud PerieFrederic TaitheYacine FarhatAnne-Laure MilletPascal CintasGuilhem SoléMarco SpinazziFlorence EsselinDimitri RenardSabrina SacconiAndra EzaruEdoardo MalfattiMartial MallaretLaurent MagyEva DiabPhilippe MerleMaud MichaudMaxime FournierAleksandra Nadaj PaklezaJean-Baptiste ChansonClaire LefeuvrePascal LaforetPascale RichardDamien SternbergRocio-Nur Villar-QuilesTanya StojkovicBruno Eymard
• Organismes : Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Physiopathologie et génétique du neurone et du muscle / Pathophysiology and Genetics of Neuron and Muscle CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Unité de Biologie Fonctionnelle et Adaptative Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en Myologie – U974 SU-INSERM Hospices Civils de Lyon Physiopathologie et génétique du neurone et du muscle / Pathophysiology and Genetics of Neuron and Muscle Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Service d'Electroneuromyographie et Service de Neurologie C [Hôpital Pierre Wertheimer - HCL] Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Hospices Civils de Lyon Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Hospices Civils de Lyon Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Hospices Civils de Lyon Hospices Civils de Lyon Centre Hospitalier Lyon Sud [CHU - HCL] Centre Hospitalier Lyon Sud [CHU - HCL] Hospices Civils de Lyon Hôpital de la Timone [CHU - APHM] Filière Neuromusculaire Hôpital de la Timone [CHU - APHM] Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM] Neuro-Oncologie [Hôpital de la Timone - APHM] Neuro-Oncologie [Hôpital de la Timone - APHM] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Lille Neurosciences & Cognition - U 1172 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de référence des Maladies Neuromusculaires AOC Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de référence des Maladies Neuromusculaires AOC Centre de Reference des Maladies Neuromusculaires - Atlantique Occitanie Caraïbe Centre Hospitalier Régional Universitaire de Brest Lymphocytes B, Autoimmunité et Immunothérapies Service de Neurologie [CHU Rennes] CHU Gabriel Montpied [Clermont-Ferrand] CHU Gabriel Montpied [Clermont-Ferrand] Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] CHU Charles-Nicolle Département Neurologie [CHU Toulouse] Centre de référence des Maladies Neuromusculaires AOC Centre Hospitalier Universitaire de Bordeaux Centre de reference des maladies neuromusculaires Nantes-Angers, CHU d'Angers et Nantes Hôpital Gui de Chauliac [CHU Montpellier] Service de Neurologie [CHU Nimes] Service de Neurologie [CHU Nice] Service de Neurologie [CHU Nice] IMRB - "Biologie du système neuromusculaire" [Créteil] [GIN] Grenoble Institut des Neurosciences Service de Neurologie [CHU Limoges] CHU Amiens-Picardie CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 CHU Amiens-Picardie Centre Hospitalier Régional Universitaire de Nancy CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Service de Neurologie [CHU Strasbourg] ERN EURO-NMD – European Reference Network for Rare Neuromuscular Diseases Service de Neurologie [CHU Strasbourg] ERN EURO-NMD – European Reference Network for Rare Neuromuscular Diseases Hôpital Raymond Poincaré [AP-HP] Hôpital Raymond Poincaré [AP-HP] Université Paris-Saclay UFR Sciences de la santé Simone Veil CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en Myologie – U974 SU-INSERM Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en Myologie – U974 SU-INSERM Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en Myologie – U974 SU-INSERM
• Publié dans Brain - A Journal of Neurology le 29/10/2020

---

Résumé : Congenital myasthenic syndromes (CMS) are clinically and genetically heterogeneous diseases caused by mutations affecting neuromuscular transmission. Even if the first symptoms mainly occur during childhood, adult neurologists must confront this challenging diagnosis and manage these patients throughout their adulthood. However, long-term follow-up data from large cohorts of CMS patients are lacking, and the long-term prognosis of these patients is largely unknown. We report the clinical features, diagnostic difficulties, and long-term prognosis of a French nationwide cohort of 235 adult patients with genetically confirmed CMS followed in 23 specialized neuromuscular centres. Data were retrospectively analysed. Of the 235 patients, 123 were female (52.3%). The diagnosis was made in adulthood in 139 patients, 110 of whom presented their first symptoms before the age of 18. Mean follow-up time between first symptoms and last visit was 34 years [standard deviation (SD) = 15.1]. Pathogenic variants were found in 19 disease-related genes. CHRNE-low expressor variants were the most common (23.8%), followed by variants in DOK7 (18.7%) and RAPSN (14%). Genotypes were clustered into four groups according to the initial presentation: ocular group (CHRNE-LE, CHRND, FCCMS), distal group (SCCMS), limb-girdle group (RAPSN, COLQ, DOK7, GMPPB, GFPT1), and a variable-phenotype group (MUSK, AGRN). The phenotypical features of CMS did not change throughout life. Only four genotypes had a proportion of patients requiring intensive care unit admission that exceeded 20%: RAPSN (54.8%), MUSK (50%), DOK7 (38.6%) and AGRN (25.0%). In RAPSN and MUSK patients most ICU admissions occurred before age 18 years and in DOK7 and AGRN patients at or after 18 years of age. Different patterns of disease course (stability, improvement and progressive worsening) may succeed one another in the same patient throughout life, particularly in AGRN, DOK7 and COLQ. At the last visit, 55% of SCCMS and 36.3% of DOK7 patients required ventilation; 36.3% of DOK7 patients, 25% of GMPPB patients and 20% of GFPT1 patients were wheelchair-bound; most of the patients who were both wheelchair-bound and ventilated were DOK7 patients. Six patients died in this cohort. The positive impact of therapy was striking, even in severely affected patients. In conclusion, even if motor and/or respiratory deterioration could occur in patients with initially moderate disease, particularly in DOK7, SCCMS and GFPT1 patients, the long-term prognosis for most CMS patients was favourable, with neither ventilation nor wheelchair needed at last visit. CHRNE-LE patients did not worsen during adulthood and RAPSN patients, often severely affected in early childhood, subsequently improved.

---

Fichiers liés : awae124.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/11/2024
• Auteurs : Marco SchlosserJulie GonneaudStefano PolettiRomain BouetOlga KlimeckiFabienne ColletteNatalie MarchantGaël ChételatAntoine LutzClaire AndréFlorence AllaisJulien AsselineauEider Arenaza-UrquijoSebastian BaezMartine BatchelorAxel BeaugoninMaelle BottonPierre ChampetierAnne ChocatPascal DelamillieureVincent de la SayetteMarion DelarueHarriet Demnitz-KingTiti DolmaStéphanie EgretFrancesca FelisattiEglantine Ferrand-DevougesÉric FrisonFrancis GheysenAgathe Joret PhilippeElizabeth KuhnBrigitte LandeauGwendoline LeduValérie LefrancFlorence MezengeInès MoulinetValentin OurryCassandre PalixLéo PalyGéraldine PoisnelAnne QuillardGéraldine RauchsFlorence RequierÉric SalmonCorrine SchwimmerEdelweiss TouronCaitlin WareTim Whitfield
• Organismes : University College London [UCL] Université de Genève = University of Geneva Physiopathologie et imagerie des troubles neurologiques Université de Caen Normandie Institut Blood and Brain @ Caen-Normandie [Caen] GIP Cyceron Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center University of Geneva Medical School Université de Liège = University of Liège = Universiteit van Luik = Universität Lüttich CRC Human imaging : Cyclotron Research Center Human Imaging [GIGA, Université de Liège] University College London [UCL] Physiopathologie et imagerie des troubles neurologiques GIP Cyceron Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Physiopathologie et imagerie des troubles neurologiques GIP Cyceron Bordeaux population health Centre Hospitalier Universitaire de Bordeaux Mayo Clinic [Rochester] Université de Caen Normandie Physiopathologie et imagerie des troubles neurologiques Institut Blood and Brain @ Caen-Normandie [Caen] Neuropsychologie et imagerie de la mémoire humaine GIP Cyceron Physiopathologie et imagerie des troubles neurologiques Institut Blood and Brain @ Caen-Normandie [Caen] GIP Cyceron Service de psychiatrie [CHU Caen] Université de Caen Normandie Service de Neurologie [CHU Caen]
• Publié dans Scientific Reports le 26/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/11/2024
• Auteurs : Maëna Le CorvecMarwin FarrugiaEric Nguyen-KhacJean-Marc RégimbeauAbdennaceur DhahriDenis ChatelainLitavan KhamphommalaAnne-Lise GautierNathalie Le BerreSébastien FreyJean-Pierre BronowickiLaurent BrunaudChloé MaréchalMarie-Cécile BlanchetVincent FreringJean DelwaideLaurent KohnenAlexandre HaumannPhilippe DelvenneMarine Sarfati-LebretonHugues TarielJérôme BernardAlexis ToullecJérôme BoursierPierre BedossaPhilippe GualRodolphe AntyAntonio Iannelli
• Organismes : DIAFIR Centre méditerranéen de médecine moléculaire CHU Amiens-Picardie Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 UPJV Simplification des soins chez les patients complexes - UR UPJV 7518 Chirurgie digestive [CHU Amiens] Chirurgie digestive [CHU Amiens] Simplification des soins chez les patients complexes - UR UPJV 7518 Anatomie et Cytologie Pathologiques [CHU Amiens] CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 Simplification des soins chez les patients complexes - UR UPJV 7518 Centre Hospitalier Privé Saint-Grégoire [Saint-Gregoire] Centre Hospitalier Privé Saint-Grégoire [Saint-Gregoire] Hôpital Archet 2 [Nice] Université Côte d'Azur Centre Hospitalier Universitaire de Nice Imagerie Adaptative Diagnostique et Interventionnelle Centre Hospitalier Régional Universitaire de Nancy Nutrition-Génétique et Exposition aux Risques Environnementaux Centre Hospitalier Régional Universitaire de Nancy Imagerie Adaptative Diagnostique et Interventionnelle Centre Hospitalier Régional Universitaire de Nancy Clinique de la Sauvegarde [Lyon] Clinique de la Sauvegarde [Lyon] Centre Hospitalier Universitaire de Liège Centre Hospitalier Universitaire de Liège Centre Hospitalier Universitaire de Liège Université de Liège = University of Liège = Universiteit van Luik = Universität Lüttich Centre Hospitalier Universitaire de Liège Université d'Angers Centre Hospitalier Universitaire d'Angers DIAFIR DIAFIR DIAFIR Université d'Angers Centre Hospitalier Universitaire d'Angers Hôpital Beaujon [AP-HP] Centre méditerranéen de médecine moléculaire Centre méditerranéen de médecine moléculaire Centre méditerranéen de médecine moléculaire
• Publié dans Scientific Reports le 26/10/2020

---

Résumé : Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in individuals with obesity. Sexual dimorphism is present in MASLD. A noninvasive test to diagnose the severity of the disease, in particular the presence of Metabolic dysfunction-associated steatohepatitis (MASH), is lacking. This European multicenter prospective study uses a blood test based on mid-infrared (MIR) metabolic fingerprinting of individuals with severe or morbid obesity to diagnose MASH. Three hundred eighty-two individuals with severe or morbid obesity undergoing bariatric surgery were enrolled prospectively. Liver biopsies were obtained during surgery and assessed centrally. An algorithm was defined to calculate a score from the recorded MIR spectrum and to establish a diagnostic threshold to classify patients with MASH. Among the women (n = 217), MASH was diagnosed in 14.3% of cases. For women, the performance in terms of AUC were 0.83 and 0.82 in the calibration and validation groups, respectively. For a threshold of 0.1817, sensitivities were 86% and 70%, specificities were 81% and 75%, PPV were 43% and 32%, NPV were 97% and 94% and ACC were 82% and 74% for the calibration and validation groups, respectively. For men (n = 78; MASH: 33.3%), the performance of the spectral model was poor. The metabolic fingerprint obtained by MIR spectroscopy can rule out MASH in women with severe or morbid obesity. Its value in men needs new studies.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/11/2024
• Auteurs : Pierre DurozardAdil MaaroufW ZaaraouiJan-Patrick StellmannClémence BoutièreAudrey RicoSarah DemortièreMaxime GuyeArnaud Le TroterHugo DaryJean-Philippe RanjevaBertrand AudoinJean Pelletier
• Organismes : Centre de résonance magnétique biologique et médicale Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM]
• Publié dans Investigative Radiology le 31/10/2020

---

Résumé : Objectives Compelling evidence indicates a significant involvement of cortical lesions in the progressive phase of multiple sclerosis (MS), significantly contributing to late-stage disability. Despite the promise of ultra-high-field magnetic resonance imaging (MRI) in detecting cortical lesions, current evidence falls short in providing insights into the existence of such lesions during the early stages of MS or their underlying cause. This study delineated, at the early stage of MS, (1) the prevalence and spatial distribution of cortical lesions identified by 7 T MRI, (2) their relationship with white matter lesions, and (3) their clinical implications. Materials and Methods Twenty individuals with early-stage relapsing-remitting MS (disease duration <1 year) underwent a 7 T MRI session involving T1-weighted MP2RAGE, T2*-weighted multiGRE, and T2-weighted FLAIR sequences for cortical and white matter segmentation. Disability assessments included the Expanded Disability Status Scale, the Multiple Sclerosis Functional Composite, and an extensive evaluation of cognitive function. Results Cortical lesions were detected in 15 of 20 patients (75%). MP2RAGE revealed a total of 190 intracortical lesions (median, 4 lesions/case [range, 0–44]) and 216 leukocortical lesions (median, 2 lesions/case [range, 0–75]). Although the number of white matter lesions correlated with the total number of leukocortical lesions ( r = 0.91, P < 0.001), no correlation was observed between the number of white matter or leukocortical lesions and the number of intracortical lesions. Furthermore, the number of leukocortical lesions but not intracortical or white-matter lesions was significantly correlated with cognitive impairment ( r = 0.63, P = 0.04, corrected for multiple comparisons). Conclusions This study highlights the notable prevalence of cortical lesions at the early stage of MS identified by 7 T MRI. There may be a potential divergence in the underlying pathophysiological mechanisms driving distinct lesion types, notably between intracortical lesions and white matter/leukocortical lesions. Moreover, during the early disease phase, leukocortical lesions more effectively accounted for cognitive deficits.

---

Fichiers liés : 2024_Investigative_Radiology.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2024
• Auteurs : Raphaël GarinPierre-Jean BouvetBeatrice TomasiPhilippe ForjonelCharles Vanwynsberghe
• Organismes : Systèmes Embarqués, Acoustique et Télécommunications Systèmes Embarqués, Acoustique et Télécommunications Systèmes Embarqués, Acoustique et Télécommunications Norwegian Research Center Systèmes Embarqués, Acoustique et Télécommunications Systèmes Embarqués, Acoustique et Télécommunications Technology Innovation Institute [Abu Dhabi]
• Publié dans Journal of Marine Science and Engineering le 29/10/2020

---

Résumé : Underwater unmanned vehicles are complementary with human presence and manned vehicles for deeper and more complex environments. An autonomous underwater vechicle (AUV) has automation and long-range capacity compared to a cable-guided remotely operated vehicle (ROV). Navigation of AUVs is challenging due to the high absorption of radio-frequency signals underwater and the absence of a global navigation satellite system (GNSS). As a result, most navigation algorithms rely on inertial and acoustic signals; precise localization is then costly in addition to being independent from acoustic data communication. The purpose of this paper is to propose and analyze the performance of a novel low-cost simultaneous communication and localization algorithm. The considered scenario consists of an AUV that acoustically sends sensor or status data to a single fixed beacon. By estimating the Doppler shift and the range from this data exchange, the algorithm can provide a location estimate of the AUV. Using a robust state estimator, we analyze the algorithm over a survey path used for AUV mission planning both in numerical simulations and at-sea experiments.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2024
• Auteurs : Nicolas PeschanskiFlorian ZoresJacques BoddaertBénedicte DouayClément DelmasAmaury BroussierDelphine DouilletEmmanuelle BerthelotThomas GilbertCédric Gil-JardinéVincent AuffretLaure JolyJérémy GuénézanMichel GalinierMarion PépinPhilippe Le ConteNicolas GirerdFrédéric RocaMathieu OberlinPatrick JourdainGeoffroy RousseauNicolas LamblinBarbara VilloingFrédéric MouquetXavier DubucsFrançois RoubilleMaxime JonchierRémi SabatierSaïd LaribiMuriel SalvatTahar ChouihedJean-Baptiste Bouillon-MinoisAnthony ChauvinPierrick Le Borgne
• Organismes : Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Groupe Médical Spécialisé Le Premium [Strasbourg] CHU Pitié-Salpêtrière [AP-HP] Hôpital Beaujon [AP-HP] Institut des Maladies Métaboliques et Casdiovasculaires Institut Mondor de Recherche Biomédicale MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Research on Healthcare Performance Institut de Santé Publique, d'Epidémiologie et de Développement Bordeaux population health Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Défaillance Cardiovasculaire Aiguë et Chronique Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Institut des Maladies Métaboliques et Casdiovasculaires Gériatrie [AP-HP Ambroise-Paré] Université de Versailles Saint-Quentin-en-Yvelines Université Paris-Saclay Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Défaillance Cardiovasculaire Aiguë et Chronique Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] French-Clinical Research Infrastructure Network - F-CRIN [Paris] Endothélium, valvulopathies et insuffisance cardiaque CHU Rouen Centre Hospitalier de Sélestat - GHSO [Sélestat] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Régional Universitaire [CHU Lille] AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris] Hôpital Privé Le Bois Ramsay Santé [Lille] Centre Hospitalier Universitaire de Toulouse Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Hôpitaux La Rochelle Ré Aunis [Groupe hospitalier littoral Atlantique] Service de cardiologie et de pathologie vasculaire [CHU Caen] Centre Hospitalier Régional Universitaire de Tours CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Défaillance Cardiovasculaire Aiguë et Chronique Laboratoire de Psychologie Sociale et Cognitive Hôpital Lariboisière-Fernand-Widal [APHP] Hôpital de Hautepierre [Strasbourg]
• Publié dans Archives of cardiovascular diseases le 30/10/2020

---

Résumé : Acute heart failure (AHF) is a complex, multifactorial syndromic condition that, until now, did not have a consensual definition [1], [2]. The difficulties in agreeing on a consensual definition of AHF also apply to research, since depending on the application of the field of investigation, the target populations concerned and the therapeutic goals or pathophysiological knowledge sought, the elements defining heart failure (HF) vary, especially among older patients. Thus, although the advent of echocardiography has made it possible to characterize disturbances in myocardial relaxation and altered ventricular filling, marking the birth of the concept of HF with preserved ejection fraction (HFpEF) versus HF with reduced ejection fraction (HFrEF), the different clinical presentations do not always make it possible to determine whether myocardial failure corresponds to a disease of ventricular filling of vascular origin [3].AHF is most often characterized by dyspnoea, lower limb oedema and/or intense asthenia. It is a common presentation in emergency departments (EDs) and has become a major public health problem as its incidence and prevalence rise in line with an aging population in all developed countries. AHF represents a growing medico-economic burden and is associated with high morbidity and mortality [4]. Currently, AHF is the main reason for hospital admissions in patients aged > 65 years and acute cardiogenic pulmonary oedema accounts for approximately 1% of ED visits [3], [4], involving approximately 200,000 patients per year in France (including 5% of the French population aged 75–85 years and 10% of those aged > 85 years) [5]. HF is a progressive pathology linked to aging, with mortality rising by 10% each year [6]. Indeed, the mortality rate remains appalling, reaching up to 12% during the hospital stay, 8–20% in the 2 months following hospitalization for an episode of AHF, and reaching 25–50% in the first 5 years after initial diagnosis. Moreover, mortality is increased in the presence of associated comorbidities such as anaemia, hypercholesterolemia or renal dysfunction, all of which become more frequent with age [3], [4], [6], [7].

---

Fichiers liés : 2024 Peschanski et al., 2023 SFMU.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2024
• Auteurs : Bruno RevolThéo WillemanMarc ManceauVéronique Dumestre-TouletJean-Michel GaulierHélène Eysseric-GuérinNathalie Fouilhé Sam-LaïChadi AbbaraDelphine AllorgeJean-Claude AlvarezAlice AmelineAnne BarretEmilie BerlandCélian BertinThierry BesnardFabien BevalotCamille Billet-ChatenayAlexandra BoucherÉmilie BouquetJoanna BourgineBertrand BrunetAnne-Sylvie CaousAlexandre CesbronLauriane CharuelMarjorie ChezeAntony Citterio-QuentinPhilippe Collon-FabieEric DaillyAmélie DaveluyGrégory DeffontaineMartine DelageXavier DelavenneFlorence DescampsJuliette DescoeurGuillaume DeslandesMarc DeveauxBernadette DevosChristophe DocheCéline EidenAurélie FouleyYvan GaillardNicolas GambierCatherine GanièreMarie GérardinJean-Pierre GoulléPascal GuerardGuillaume HoizeyLuc HumbertLaurent ImbertMarie-France KerguerisPascal KintzFlorian KlinzigLaurence Labat-DeveauxBruno LacarelleChristian LacroixDenis LamiableMichel LavitReynald Le BoisselierAnne Le BouilCatherine Le MeurSandrine LefeuvreBénédicte LelièvreVéronique Lelong-BoulouardAnne-Sophie Lemaire-HurtelMagalie LoilierVincent LopezClaire Martin-MolinsHélène MartyOlivier MathieuJean-Claude Mathieu-DaudéYves MaurasNathalie MilanAurélie MoalIsabelle MorelPatrick MuraAnne-Laure Pelissier-AlicotGilbert PépinMartine PerrinAnne PeyreAlain PineauLiselotte PochardRop PokCatherine Ragoucy-SenglerRaphaël RayerNassima RedjimiEmilie RomanCarine RousselSandrine SabiniElodie SaussereauJulien Scala-BertolaPauline SibilleMichel SpadariJohan ThieryKarine TitierAlain TurcantPierrick VacherNicolas VenisseOphélie VieiraPascale Visinoni
• Organismes : Université Grenoble Alpes - UFR Médecine CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Hypoxie et PhysioPathologie CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Centre d'Investigation Clinique [Grenoble] Laboratoire ToxGen Centre Hospitalier Régional Universitaire [CHU Lille] CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Université Grenoble Alpes CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Département de Pharmacologie-Toxicologie [CHU Angers] Impact de l'environnement chimique sur la santé humaine - ULR 4483 Plateforme de spectrométrie de masse [Garches] Hôpital Raymond Poincaré [AP-HP] Institut de Médecine Légale [Strasbourg] Laboratoire de pharmacologie et toxicologie neurocardiovasculaire CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble CHU Gabriel Montpied [Clermont-Ferrand] Université Clermont Auvergne Neuro-Dol Laboratoire Lat Lumtox Hospices Civils de Lyon Laboratoire de neurosciences expérimentales et cliniques [U 1084] CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Service de pharmacologie clinique et vigilances [CHU de Poitiers] Département de Pharmacologie [CHU Caen] Université Jean Monnet - Saint-Étienne Santé Ingénierie Biologie Saint-Etienne Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Institut de Neurosciences des Systèmes Institut de Neurosciences des Systèmes
• Publié dans Public Health le 26/10/2020

---

Résumé : Objective: To describe analgesic-related deaths in France and report trends over a 10-year period. Study design: The DTA (“Décès Toxiques par Antalgiques”) register is a French database of analgesic-related deaths among people without a history of drug abuse, reported by forensic toxicology experts. Methods: We included analgesic-related deaths occurring from January 2013 to December 2022 in France. Subject demographic characteristics and medical history, forensic autopsy findings, and toxicology reports were evaluated. Results: Among the 1036 deceased individuals (mean [SD] age, 48.3 [15.6] years), there were slightly more women than men (M:F sex ratio, 0.89:1). Over the entire study period, tramadol was the leading cause of death, ahead of morphine. A relative increase in oxycodone-related mortality was observed (from 6.8% in 2013 to 21.1% in 2022) compared to a progressive decrease in tramadol, morphine, and codeine-related deaths (from 43.2%, 31.1% and 24.3% in 2013 to 37.5%, 26.6% and 20.3% in 2022, respectively). However, no statistically significant variations were found (Chi-squared tests of homogeneity). Other analgesics (buprenorphine, dihydrocodeine, fentanyl, gabapentin, ketamine, methadone, nefopam, and pregabalin) were also implicated in deaths, but with low and stable rates over the period studied. Conclusions: In France, no increase in fentanyl-related deaths and only a non-significant increase in oxycodone-related deaths were observed over the period 2013–2022. Tramadol was the leading cause of analgesic-related deaths throughout this period. Although close monitoring is still required, particularly for oxycodone, our data do not support the hypothesis of an opioid crisis in France.

---

Fichiers liés : 1-s2.0-S0033350624003652-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2024
• Auteurs : Hugo PeyreNicolas HoertelBaptiste PignonAli AmadJean-Luc RoelandtImane BenradiaPierre ThomasGuillaume VaivaPierre-Alexis GeoffroyEmilie OliéPhilippe Courtet
• Organismes : Centre d’Excellence sur l’Autisme et les Troubles du Neurodéveloppement [CHU Montpellier] Centre de recherche en épidémiologie et santé des populations Centre Hospitalier Régional Universitaire [Montpellier] Institut de psychiatrie et neurosciences de Paris GHU AP-HP Centre Université Paris Cité Institut Mondor de Recherche Biomédicale Hôpital Henri Mondor Fondation FondaMental [Créteil] Lille Neurosciences & Cognition - U 1172 Fédération régionale de la recherche en psychiatrie et santé mentale Hauts-de-France [Lille] Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables Centre Collaborateur de l'Organisation Mondiale de la Santé pour la recherche et la formation en santé mentale Etablissement Public de Santé Mentale de Lille-Métropole [Armentières] Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables Centre Collaborateur de l'Organisation Mondiale de la Santé pour la recherche et la formation en santé mentale Etablissement Public de Santé Mentale de Lille-Métropole [Armentières] Lille Neurosciences & Cognition - U 1172 Fédération régionale de la recherche en psychiatrie et santé mentale Hauts-de-France [Lille] Lille Neurosciences & Cognition - U 1172 Centre National de Ressources et de Résilience [Lille] Fédération régionale de la recherche en psychiatrie et santé mentale Hauts-de-France [Lille] AP-HP - Hôpital Bichat - Claude Bernard [Paris] GHU AP-HP Nord - Université Paris Cité Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] Maladies neurodéveloppementales et neurovasculaires Centre Hospitalier Régional Universitaire [Montpellier] Institut de Génomique Fonctionnelle Fondation FondaMental [Créteil] Centre Hospitalier Régional Universitaire [Montpellier] Institut de Génomique Fonctionnelle Fondation FondaMental [Créteil]
• Publié dans Journal of Clinical Psychiatry le 27/10/2020

---

Résumé : Background: This study explores among individuals with a major depressive episode (MDE) the potential impact of mixed features on the risk of suicide attempt, suicidal thoughts, self-harm intentions, and thoughts of death. Methods: Data from the French Mental Health in General Population (MHGP) survey (1999-2003) were analyzed, including 128 participants meeting DSM 5 criteria for MDE with mixed features (MDE with at least 3 manic symptoms) and 3,312 participants experiencing MDE without mixed features. Our primary analysis focused on suicide attempt, with additional examination of recent suicidal thoughts, self-harm intentions, and thoughts of death. Multivariable regression models were performed to adjust for potential confounding variables, including sociodemographics, previous suicide attempt, number of depressive symptoms, and psychiatric comorbidity. Results: MDE with mixed features was significantly associated with an increased risk of suicide attempt (adjusted odds ratio [AOR] = 1.69; 95% CI, 1.26-2.25). This association did not significantly differ between men and women. Furthermore, the number of manic symptoms demonstrated a dose-dependent relationship with an increased risk of suicide attempt (AOR = 1.18; 95% CI, 1.07-1.30; P < .001). Mixed features were also associated with suicide attempt among individuals with MDE and without recent suicidal thoughts (AOR = 2.74; 95% CI, 1.36-5.54). Conclusion: This study underscores the importance of assessing mixed features when evaluating the risk of suicide attempt in individuals with MDE. Mechanisms underlying this association might be independent of progression from thoughts of death to suicidal thoughts, suicidal intention, and ultimately, suicide attempt.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2024
• Auteurs : Bruno RevolT. WillemanM. ManceauV. Dumestre-TouletJ.-M. GaulierH. Eysseric-GuérinNathalie Fouilhé Sam-LaïChadi AbbaraDelphine AllorgeJean-Claude AlvarezAlice AmelineAnne BarretEmilie BerlandCélian BertinThierry BesnardFabien BevalotCamille Billet-ChatenayAlexandra BoucherEmilie BouquetJoanna BourgineBertrand BrunetAnne-Sylvie CaousAlexandre CesbronLauriane CharuelMarjorie ChezeAntony Citterio-QuentinPhilippe Collon-FabieEric DaillyAmélie DaveluyGrégory DeffontaineMartine DelageXavier DelavenneFlorence DescampsJuliette DescoeurGuillaume DeslandesMarc DeveauxBernadette DevosChristophe DocheCéline EidenAurélie FouleyYvan GaillardNicolas GambierCatherine GanièreMarie GérardinJean-Pierre GoulléPascal GuerardGuillaume HoizeyLuc HumbertLaurent ImbertMarie-France KerguerisPascal KintzFlorian KlinzigLaurence LabatBruno LacarelleChristian LacroixDenis LamiableMichel LavitReynald Le BoisselierAnne Le BouilCatherine Le MeurS. LefeuvreBénédicte LelièvreV. Lelong-BoulouardAnne-Sophie Lemaire-HurtelMagalie LoilierVincent LopezClaire Martin-MolinsHélène MartyOlivier MathieuJean-Claude Mathieu-DaudéYves MaurasNathalie MilanAurélie MoalIsabelle MorelPatrick MuraAnne-Laure Pelissier-AlicotGilbert PépinMartine PerrinAnne PeyreAlain PineauLiselotte PochardRop PokCatherine Ragoucy-SenglerRaphaël RayerNassima RedjimiEmilie RomanCarine RousselSandrine SabiniElodie SaussereauJ. Scala-BertolaPauline SibilleMichel SpadariJohan ThieryKarine TitierAlain TurcantPierrick VacherNicolas VenisseOphélie VieiraPascale Visinoni
• Organismes : Université Grenoble Alpes - UFR Médecine CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Hypoxie et PhysioPathologie CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Laboratoire de Physique des Lasers Service de Pharmacologie, toxicologie et pharmacovigilance [CHU Limoges] CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Département de Pharmacologie-Toxicologie [CHU Angers] Impact de l'environnement chimique sur la santé humaine - ULR 4483 Plateforme de spectrométrie de masse [Garches] Hôpital Raymond Poincaré [AP-HP] Institut de Médecine Légale [Strasbourg] Laboratoire de pharmacologie et toxicologie neurocardiovasculaire CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Service National de la Police Scientifique CHU Gabriel Montpied [Clermont-Ferrand] Université Clermont Auvergne Neuro-Dol Faculté de Médecine - Clermont-Auvergne Institut Analgesia Laboratoire Lat Lumtox Hospices Civils de Lyon Laboratoire de neurosciences expérimentales et cliniques [U 1084] CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Service de pharmacologie clinique et vigilances [CHU de Poitiers] Département de Pharmacologie [CHU Caen] CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 0802) Laboratoire de toxicologie et pharmacocinétique [Unité médicale de toxicologie, service du CHU de Poitiers] CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Interaction Homme Environnement Santé [Équipe du laboratoire EBI Poitiers]
• Publié dans Public Health le 26/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2024
• Auteurs : Kassandra ZachosOphélia GodinJaehyoung ChoiJae JungBruno AouizerateValérie AubinFrank BellivierR. Raoul BelzeauxPhilippe CourtetCaroline DubertretBruno EtainEmmanuel HaffenA. Antoine LefrerePierre-Michel LlorcaEmilie OliéMircea PolosanLudovic SamalinRaymund SchwanPaul RouxCaroline BarauJean Romain RichardRyad TamouzaMarion LeboyerAna AndreazzaB. EtainE. OliéMarion LeboyerE. HaffenPierre-Michel LlorcaV. BarteauS. BensalemO. GodinH. LaouamriK. SouryisS. HotierAmandine PelletierF. HergetaJ. PetrucciL. WillaumeF. BellivierV. HennionE. MarlingeJ. MeheustA. RichardM. CarminatiH. FrancisqueC. DubertretN. MazerC. PortalierC. ScognamiglioA. BingP. LaurentS. GardKatia M'BailaraC. ElkaelF. HoorelbekeI. MinoisJ. SportichN. da RosL. BoukhobzaPhilippe CourtetS. DenatB. DeffinisD. DucasseM. GachetA. LengvenytéF. MolièreL. NassG. TarquiniA. LefrereE. MoreauJ. PastolF. GroppiH. PolomeniJ. BaubergL. LescalierI. MuraccioliA. SurayR. CohenJ.P. KahnM. MilazzoO. Wajsbrot-ElgrabliThierry BougerolA. PouchonA. BertrandB. FredembachA. SuisseQ. DenoualM. PolosanA.M. GalliotL. BrehonG. BonnyL. DurandV. FeugaN. KayserP. RouxV. AubinI. CussacM.A. DupontJ. LoftusI. MedecinL. SamalinP.M. LlorcaM. MennetrierT. BonnetD. LacelleM. VayssiéC. BealO. Blanc
• Organismes : University of Toronto IMRB - "Biologie du système neuromusculaire" [Créteil] Fondation FondaMental [Créteil] University of Toronto University of Toronto Centre hospitalier Charles Perrens [Bordeaux] Nutrition et Neurobiologie intégrée Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Centre Hospitalier Princesse Grace Optimisation thérapeutique en Neuropsychopharmacologie Fondation FondaMental [Créteil] Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] Hôpital Lariboisière-Fernand-Widal [APHP] Fondation FondaMental [Créteil] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Institut de Génomique Fonctionnelle Fondation FondaMental [Créteil] Hôpital Louis Mourier - AP-HP [Colombes] Institut de psychiatrie et neurosciences de Paris Fondation FondaMental [Créteil] Université Sorbonne Paris Cité Optimisation thérapeutique en Neuropsychopharmacologie GHU AP-HP Nord - Université Paris Cité Fondation FondaMental [Créteil] Hôpital Lariboisière-Fernand-Widal [APHP] Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) Fondation FondaMental [Créteil] Centre d'Investigation Clinique de Besançon Fondation FondaMental [Créteil] Assistance Publique - Hôpitaux de Marseille Institut de Neurosciences de la Timone Fondation FondaMental [Créteil] CHU Clermont-Ferrand Université Clermont Auvergne Institut Pascal Centre Hospitalier Régional Universitaire [Montpellier] Institut de Génomique Fonctionnelle Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] [GIN] Grenoble Institut des Neurosciences CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Fondation FondaMental [Créteil] Institut Pascal CHU Clermont-Ferrand Université Clermont Auvergne Centre Psychothérapique de Nancy [Laxou] Imagerie Adaptative Diagnostique et Interventionnelle Fondation FondaMental [Créteil] Centre Hospitalier de Versailles André Mignot Centre de recherche en épidémiologie et santé des populations Plateforme de Ressources Biologiques [Henri Mondor AP-HP, Créteil] Institut Mondor de Recherche Biomédicale Hôpital Henri Mondor Institut Mondor de Recherche Biomédicale Hôpital Henri Mondor Institut Mondor de Recherche Biomédicale Hôpital Henri Mondor Fondation FondaMental [Créteil] University of Toronto Centre Psychothérapique de Nancy [Laxou] Centre Psychothérapique de Nancy [Laxou] Centre Psychothérapique de Nancy [Laxou] Centre Psychothérapique de Nancy [Laxou]
• Publié dans Journal of Affective Disorders le 31/10/2020

---

Résumé : Background: Nutrition is largely affected in bipolar disorder (BD), however, there is a lack of understanding on the relationship between dietary categories, BD, and the prevalence of metabolic syndrome. The objective of this study is to examine dietary trends in BD and it is hypothesized that diets with increased consumption of seafood and high-fiber carbohydrates will be correlated to improved patient outcomes, and a lower frequency of metabolic syndrome. Methods: This retrospective cohort study includes two French cohorts. The primary cohort, FACE-BD, includes 268 stable BD patients. The second cohort, I-GIVE, includes healthy controls, both stable and acute BD and schizophrenia patients. Four dietary categories were assessed: meat, seafood, low-fiber and high-fiber carbohydrates. Dietary data from two food frequency questionnaires were normalized using min-max scaling and assessed using various statistical analyses. Results: In our primary cohort, the increased high-fiber carbohydrate consumption was correlated to lower prevalence of metabolic syndrome and improved mood. Low-fiber carbohydrate consumption is associated with higher BMI, while higher seafood consumption was correlated to improved mood and delayed age of onset. Results were not replicated in our secondary cohort. Limitations: Our populations were small and two different dietary questionnaires were used; thus, results were used to examine similarities in trends. Conclusions: Overall, various dietary trends were associated with metabolic syndrome, BMI, lactate, mood and age of onset. Improving our understanding of nutrition in BD can provide mechanistic insight, clinically relevant nutritional guidelines for precision medicine and ultimately improve the quality of lives for those with BD.

---

Source